IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. The firm operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Mr. Eyal Shamir es el Chief Executive Officer de Icecure Medical Ltd, se unió a la empresa desde 2016.
¿Qué tal es el rendimiento del precio de la acción ICCM?
El precio actual de ICCM es de $0.3947, ha disminuido un 32.87% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Icecure Medical Ltd?
Icecure Medical Ltd pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Icecure Medical Ltd?
La capitalización bursátil actual de Icecure Medical Ltd es $27.2M
¿Es Icecure Medical Ltd una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 4 analistas han realizado calificaciones de análisis para Icecure Medical Ltd, incluyendo 2 fuerte compra, 6 compra, 1 mantener, 0 venta, y 2 fuerte venta